Warner Chilcott Targets Ranbaxy’s Osteoporosis Generic

Law360, New York (April 27, 2012, 4:02 PM EDT) -- Warner Chilcott Co. LLC on Thursday redoubled its efforts to protect its osteoporosis drug Atelvia, launching a new infringement suit accusing Ranbaxy Laboratories Ltd. of violating its patents by developing a generic version of the drug.

Warner Chilcott said in New Jersey federal court that Ranbaxy's planned launch of a competing generic version of the oral tablets used to fight osteoporosis in postmenopausal women constitutes infringement of a pair of the company's drug patents.

Ranbaxy has “committed, aided, abetted, actively induced, contributed to or participated in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.